Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease.

@article{Tallman2005HairyCL,
  title={Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease.},
  author={Martin S. Tallman and Anaadriana Zakarija},
  journal={Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis},
  year={2005},
  volume={32 1},
  pages={99-103}
}
Since its initial description approximately 50 years ago, there has been an impressive evolution in therapies for hairy cell leukemia. Long-term follow-up with 2-cholorodeoxyadenosine and 2'-deoxycoformycin demonstrates that both agents result in a high complete remission rate and overall survival. Relapse rates appear to be between 20% and 30%. Therapeutic strategies for patients with relapsed disease include retreatment with a purine analog, rituximab, or the anti-CD22 pseudomonas exotoxin A… CONTINUE READING